EA035329B1 - Способ и композиция для лечения астмы или аллергического ринита или хронической обструктивной болезни лёгких - Google Patents
Способ и композиция для лечения астмы или аллергического ринита или хронической обструктивной болезни лёгких Download PDFInfo
- Publication number
- EA035329B1 EA035329B1 EA201690738A EA201690738A EA035329B1 EA 035329 B1 EA035329 B1 EA 035329B1 EA 201690738 A EA201690738 A EA 201690738A EA 201690738 A EA201690738 A EA 201690738A EA 035329 B1 EA035329 B1 EA 035329B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- microns
- lactose
- particle size
- inhaler
- salmeterol xinafoate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 208000006673 asthma Diseases 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 11
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 9
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 9
- 239000002245 particle Substances 0.000 claims abstract description 59
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 49
- 239000008101 lactose Substances 0.000 claims abstract description 49
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000000843 powder Substances 0.000 claims abstract description 39
- 229960005018 salmeterol xinafoate Drugs 0.000 claims abstract description 35
- 229960000289 fluticasone propionate Drugs 0.000 claims abstract description 33
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 32
- 239000006185 dispersion Substances 0.000 claims abstract description 21
- 229940112141 dry powder inhaler Drugs 0.000 claims abstract description 13
- 229960004017 salmeterol Drugs 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims description 25
- YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 claims description 14
- 229940114006 fluticasone / salmeterol Drugs 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 5
- 229960001375 lactose Drugs 0.000 description 31
- 238000009826 distribution Methods 0.000 description 26
- 239000008186 active pharmaceutical agent Substances 0.000 description 15
- 229940088679 drug related substance Drugs 0.000 description 15
- 238000004891 communication Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 12
- 238000005259 measurement Methods 0.000 description 10
- 238000007789 sealing Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 125000006850 spacer group Chemical group 0.000 description 9
- 238000002604 ultrasonography Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000013543 active substance Substances 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000003466 welding Methods 0.000 description 6
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 5
- 229940090167 advair Drugs 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 229940125369 inhaled corticosteroids Drugs 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 239000012907 medicinal substance Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 238000010947 wet-dispersion method Methods 0.000 description 2
- 229950000339 xinafoate Drugs 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000013125 spirometry Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
- A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
- A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
- A61M15/0026—Hinged caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
- A61M15/0076—Mechanical counters having a display or indicator on a drum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
- A61M15/0078—Mechanical counters having a display or indicator on a strip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887589P | 2013-10-07 | 2013-10-07 | |
| US201361888301P | 2013-10-08 | 2013-10-08 | |
| PCT/US2014/059285 WO2015054124A2 (en) | 2013-10-07 | 2014-10-06 | Dry powder inhaler |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201690738A1 EA201690738A1 (ru) | 2016-08-31 |
| EA035329B1 true EA035329B1 (ru) | 2020-05-28 |
Family
ID=51743574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690738A EA035329B1 (ru) | 2013-10-07 | 2014-10-06 | Способ и композиция для лечения астмы или аллергического ринита или хронической обструктивной болезни лёгких |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9066957B2 (enExample) |
| EP (1) | EP3054920B1 (enExample) |
| JP (1) | JP6543620B2 (enExample) |
| KR (1) | KR102364945B1 (enExample) |
| CN (1) | CN105636630B (enExample) |
| AU (1) | AU2014332191B2 (enExample) |
| BR (1) | BR112016007771B1 (enExample) |
| CA (1) | CA2926432A1 (enExample) |
| CL (1) | CL2016000735A1 (enExample) |
| DK (1) | DK3054920T3 (enExample) |
| EA (1) | EA035329B1 (enExample) |
| ES (1) | ES2863198T3 (enExample) |
| HK (1) | HK1222127A1 (enExample) |
| HU (1) | HUE055042T2 (enExample) |
| IL (1) | IL244959B (enExample) |
| MX (1) | MX374870B (enExample) |
| PE (1) | PE20160543A1 (enExample) |
| PH (1) | PH12016500619B1 (enExample) |
| PL (1) | PL3054920T3 (enExample) |
| PT (1) | PT3054920T (enExample) |
| TW (1) | TWI673070B (enExample) |
| WO (1) | WO2015054124A2 (enExample) |
| ZA (1) | ZA201601960B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013036881A2 (en) | 2011-09-07 | 2013-03-14 | Syphase, Llc | Dry powder inhalation device |
| PL3054920T3 (pl) * | 2013-10-07 | 2021-07-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalator suchego proszku |
| AU356105S (en) * | 2013-11-29 | 2014-06-24 | Norton Waterford Ltd | Respiratory apparatus |
| USD769436S1 (en) * | 2013-11-29 | 2016-10-18 | Norton (Waterford) Limited | Respiratory apparatus |
| USD755367S1 (en) * | 2014-03-10 | 2016-05-03 | Civitas Therapeutics, Inc. | Indicator for an inhaler |
| USD752204S1 (en) * | 2014-03-10 | 2016-03-22 | Civitas Therapeutics, Inc. | Indicator for an inhaler |
| USD752734S1 (en) | 2014-03-10 | 2016-03-29 | Civitas Therapeutics, Inc. | Inhaler grip |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| CN107095875B (zh) * | 2016-02-23 | 2022-03-18 | 天津金耀集团有限公司 | 一种昔奈酸沙美特罗丙酸氟替卡松复方粉吸入剂组合物 |
| CN109562236B (zh) * | 2016-04-12 | 2022-04-26 | 生物合作制造公司 | 定量雾化吸入器附加设备，观察改善系统以及改善使用定量雾化吸入器中的观察的方法 |
| CN106267484A (zh) * | 2016-08-08 | 2017-01-04 | 中山市美捷时包装制品有限公司 | 一种干粉吸入装置的定量供料机构 |
| USD852947S1 (en) * | 2016-10-21 | 2019-07-02 | Norton (Waterford) Limited | Inhaler |
| USD832997S1 (en) * | 2016-10-21 | 2018-11-06 | Norton (Waterford) Limited | Inhaler |
| USD832998S1 (en) * | 2016-10-21 | 2018-11-06 | Norton (Waterford) Limited | Inhaler |
| EP3552646B1 (en) * | 2016-11-18 | 2021-07-07 | Norton (Waterford) Limited | Drug delivery device with electronics |
| USD853555S1 (en) * | 2017-01-03 | 2019-07-09 | Norton (Waterford) Limited | Inhaler |
| GB201700727D0 (en) * | 2017-01-16 | 2017-03-01 | Teva Pharma | Inhalers and airflow adaptors therefor |
| CA3057683A1 (en) | 2017-03-28 | 2018-10-04 | Concentrx Pharmaceuticals, Inc. | Devices and methods for delivering dry powder medicaments |
| CN107715264B (zh) * | 2017-10-12 | 2021-01-29 | 上海新黄河制药有限公司 | 一种粉雾剂装置制剂粉末团聚物的分散/解聚装置 |
| CN107737393B (zh) * | 2017-10-12 | 2020-08-28 | 上海新黄河制药有限公司 | 一种用于粉雾剂吸入装置的制剂雾化流道 |
| CN111542308B (zh) | 2017-12-13 | 2024-04-02 | 埃姆弗西斯进出口及分销有限公司 | 干粉吸入器 |
| USD949323S1 (en) * | 2019-07-26 | 2022-04-19 | Lupin Ltd. | Inhaler |
| USD949324S1 (en) * | 2019-07-26 | 2022-04-19 | Lupin Ltd. | Inhaler |
| USD948703S1 (en) * | 2019-07-26 | 2022-04-12 | Lupin Ltd. | Inhaler |
| USD948704S1 (en) * | 2019-07-26 | 2022-04-12 | Lupin Ltd. | Inhaler |
| USD1006214S1 (en) * | 2020-02-14 | 2023-11-28 | Aptar France Sas | Inhaler |
| USD1006213S1 (en) * | 2020-02-14 | 2023-11-28 | Aptar France Sas | Inhaler |
| WO2021219535A1 (en) * | 2020-04-27 | 2021-11-04 | Jt International Sa | Aerosol generation device |
| GB202012742D0 (en) * | 2020-08-14 | 2020-09-30 | Norton Waterford Ltd | An inhalable medicament |
| KR102767525B1 (ko) | 2022-01-24 | 2025-02-14 | 주식회사 케이티앤지 | 흡입기 |
| KR102782140B1 (ko) | 2022-08-25 | 2025-03-18 | 주식회사 케이티앤지 | 흡입기 |
| KR102783650B1 (ko) | 2022-09-14 | 2025-03-19 | 주식회사 케이티앤지 | 흡입기 |
| KR102864455B1 (ko) | 2022-09-14 | 2025-09-26 | 주식회사 케이티앤지 | 흡입기 |
| KR102885446B1 (ko) | 2022-09-19 | 2025-11-14 | 주식회사 케이티앤지 | 흡입기 |
| KR102917969B1 (ko) | 2022-12-30 | 2026-01-26 | 주식회사 케이티앤지 | 흡입기 |
| WO2025012114A1 (en) | 2023-07-07 | 2025-01-16 | Norton (Waterford) Limited | An inhalable formulation of fluticasone propionate and albuterol sulfate for the treatment of asthma |
| EP4487842A1 (en) | 2023-07-07 | 2025-01-08 | Norton (Waterford) Limited | An inhalable formulation of fluticasone propionate and albuterol sulfate for the treatment of asthma |
| AU2024294145A1 (en) | 2023-07-07 | 2025-12-04 | Norton (Waterford) Limited | An inhalable formulation of fluticasone propionate and albuterol sulfate for the treatment of asthma |
| WO2025199032A1 (en) * | 2024-03-18 | 2025-09-25 | Transpire Bio Inc. | Trigger mechanism and powder inhalation device |
| EP4678170A1 (en) | 2024-07-08 | 2026-01-14 | Norton (Waterford) Limited | A fixed-dose dry powder inhalation formulation of fluticasone propionate and albuterol sulfate for the treatment of asthma |
| WO2026013023A1 (en) | 2024-07-08 | 2026-01-15 | Norton (Waterford) Limited | A fixed-dose dry powder inhalation formulation of fluticasone propionate and albuterol sulfate for the treatment of asthma |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001097889A2 (en) * | 2000-06-23 | 2001-12-27 | Ivax Corporation | De-agglomerator for breath-actuated dry powder inhaler |
| WO2002000281A2 (en) * | 2000-06-23 | 2002-01-03 | Ivax Corporation | Medicament inhaler |
| WO2011054527A1 (en) * | 2009-11-06 | 2011-05-12 | Norton Healthcare Limited | Airflow adaptor for a breath-actuated dry powder inhaler |
| WO2011145109A1 (en) * | 2010-05-20 | 2011-11-24 | Sun Pharma Advanced Research Company Ltd., | Dry powder inhalation composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| GB0124523D0 (en) * | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
| PT1386630E (pt) * | 2002-07-31 | 2006-09-29 | Chiesi Farma Spa | Inalador em po |
| CN1694689A (zh) * | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| HUE034380T2 (en) * | 2007-04-30 | 2018-02-28 | Sun Pharma Advanced Res Co Ltd | Inhalation device |
| JP2008301847A (ja) * | 2007-06-05 | 2008-12-18 | Canon Inc | 吸入装置及びその駆動方法 |
| US20100329996A1 (en) * | 2007-09-12 | 2010-12-30 | Glaxo Group Limited | Novel Combination of Therapeutic Agents |
| PT2435025T (pt) * | 2009-05-29 | 2016-11-11 | Pearl Therapeutics Inc | Administração, por via respiratória, de agentes activos |
| PL3054920T3 (pl) * | 2013-10-07 | 2021-07-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalator suchego proszku |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
-
2014
- 2014-10-06 PL PL14786419T patent/PL3054920T3/pl unknown
- 2014-10-06 CA CA2926432A patent/CA2926432A1/en not_active Withdrawn
- 2014-10-06 EA EA201690738A patent/EA035329B1/ru not_active IP Right Cessation
- 2014-10-06 HK HK16110356.9A patent/HK1222127A1/zh unknown
- 2014-10-06 MX MX2016004316A patent/MX374870B/es active IP Right Grant
- 2014-10-06 WO PCT/US2014/059285 patent/WO2015054124A2/en not_active Ceased
- 2014-10-06 ES ES14786419T patent/ES2863198T3/es active Active
- 2014-10-06 BR BR112016007771-7A patent/BR112016007771B1/pt active IP Right Grant
- 2014-10-06 PT PT147864193T patent/PT3054920T/pt unknown
- 2014-10-06 PE PE2016000408A patent/PE20160543A1/es unknown
- 2014-10-06 US US14/507,210 patent/US9066957B2/en active Active
- 2014-10-06 JP JP2016520581A patent/JP6543620B2/ja not_active Expired - Fee Related
- 2014-10-06 CN CN201480055333.2A patent/CN105636630B/zh active Active
- 2014-10-06 KR KR1020167011976A patent/KR102364945B1/ko active Active
- 2014-10-06 DK DK14786419.3T patent/DK3054920T3/da active
- 2014-10-06 EP EP14786419.3A patent/EP3054920B1/en active Active
- 2014-10-06 HU HUE14786419A patent/HUE055042T2/hu unknown
- 2014-10-06 US US15/027,660 patent/US20160243320A1/en not_active Abandoned
- 2014-10-06 AU AU2014332191A patent/AU2014332191B2/en not_active Ceased
- 2014-10-07 TW TW103134890A patent/TWI673070B/zh not_active IP Right Cessation
-
2016
- 2016-03-22 ZA ZA2016/01960A patent/ZA201601960B/en unknown
- 2016-03-30 CL CL2016000735A patent/CL2016000735A1/es unknown
- 2016-04-05 PH PH12016500619A patent/PH12016500619B1/en unknown
- 2016-04-06 IL IL244959A patent/IL244959B/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001097889A2 (en) * | 2000-06-23 | 2001-12-27 | Ivax Corporation | De-agglomerator for breath-actuated dry powder inhaler |
| WO2002000281A2 (en) * | 2000-06-23 | 2002-01-03 | Ivax Corporation | Medicament inhaler |
| WO2011054527A1 (en) * | 2009-11-06 | 2011-05-12 | Norton Healthcare Limited | Airflow adaptor for a breath-actuated dry powder inhaler |
| WO2011145109A1 (en) * | 2010-05-20 | 2011-11-24 | Sun Pharma Advanced Research Company Ltd., | Dry powder inhalation composition |
Non-Patent Citations (2)
| Title |
|---|
| Copley Scientific: "Quality solutions for inhaler testing", 2012, pages 1-108, XP002740714, Retrieved from the Internet: URL: http://www.copleyscientific.com/files/ww/brochures/Inhaler Brochure 2012_Low Res_.pdf [retrieved on 2015-10-06] page 17 - page 22, page 82 - page 83 * |
| NELSON, H.S. ; WOLFE, J.D. ; GROSS, G. ; GREOS, L.S. ; BAITINGER, L. ; SCOTT, C. ; DORINSKY, P.: "Efficacy and safety of fluticasone propionate 44 1/4g/salmeterol 21 1/4g administeredin a hydrofluoroalkane metered-dose inhaleras an initial asthma maintenance treatment", ANNALS OF ALLERGY, ASTHMA & IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 91, no. 3, 1 September 2003 (2003-09-01), AMSTERDAM, NL, pages 263 - 269, XP026974851, ISSN: 1081-1206 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014332191B2 (en) | Dry powder inhaler | |
| DK3079744T3 (en) | dry powder inhaler | |
| AU2016209363B2 (en) | Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat | |
| AU2014361087B2 (en) | Inhalable medicaments | |
| HK1242605A1 (en) | Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat | |
| HK1219444B (en) | Dry powder inhaler | |
| NZ718315B2 (en) | Dry powder inhaler | |
| HK1227340B (en) | Dry powder inhaler | |
| HK1228273A1 (en) | Inhalable medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |